234 715

Cited 2 times in

Clinical and Angiographic Outcomes of the First Korean-made Sirolimus-Eluting Coronary Stent with Abluminal Bioresorbable Polymer

Authors
Yang, HM  | Seo, KW  | Yoon, J | Kim, HS | Chang, K | Lim, HS  | Choi, BJ  | Choi, SY  | Yoon, MH  | Lee, SH | Ahn, SG | Youn, YJ | Lee, JW | Koo, BK | Park, KW | Yang, HM | Han, JK | Seung, KB | Chung, WS | Kim, PJ | Koh, YS | Park, HJ | Tahk, SJ
Citation
Korean circulation journal, 47(6). : 898-906, 2017
Journal Title
Korean circulation journal
ISSN
1738-55201738-5555
Abstract
BACKGROUND AND OBJECTIVES: This trial evaluated the safety and efficacy of the Genoss drug-eluting coronary stent.
METHODS: This study was a prospective, multicenter, randomized trial with a 1:1 ratio of Genoss drug-eluting stent (DES) and Promus Element. Inclusion criteria were the presence of stable angina, unstable angina, or silent ischemia. Angiographic inclusion criteria were de novo coronary stenotic lesion with diameter stenosis >50%, reference vessel diameter of 2.5-4.0 mm, and lesion length RESULTS: We enrolled 38 patients for the Genoss DES group and 39 patients for the Promus Element group. In-stent late lumen loss at 9 months was not significantly different between the 2 groups (0.11+/-0.25 vs. 0.16+/-0.43 mm, p=0.567). There was no MI or stent thrombosis in either group. The rates of death (2.6% vs. 0%, p=0.494), TLR (2.6% vs. 2.6%, p=1.000), and TVR (7.9% vs. 2.6%, p=0.358) at 9 months were not significantly different.
CONCLUSION: This first-in-patient study of the Genoss DES stent showed excellent angiographic outcomes for in-stent late lumen loss and major adverse cardiac events over a 9-month follow-up.
Keywords
DOI
10.4070/kcj.2017.0094
PMID
29035435
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Cardiology
Ajou Authors
서, 경우  |  양, 형모  |  윤, 명호  |  임, 홍석  |  최, 병주  |  최, 소연  |  탁, 승제
Full Text Link
Files in This Item:
29035435.pdfDownload
Export

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse